Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Medprin Regenerative Medical Technologies Co Ltd (301033)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
35.00 +0.17    +0.49%
02:56:48 - Closed. Currency in CNY ( Disclaimer )
Type:  Equity
Market:  China
ISIN:  CNE100004NB8 
  • Volume: 1,115,263
  • Bid/Ask: 35.00 / 34.97
  • Day's Range: 34.03 - 35.36
Medprin Regenerative Medical Technologies Co 35.00 +0.17 +0.49%

Medprin Regenerative Medical Technologies Co Ltd Company Profile

 
Get an in-depth profile of Medprin Regenerative Medical Technologies Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

279

Equity Type

ORD

Medprin Regenerative Medical Technologies Co., Ltd. engages in the research, development, manufacture, and sale of implantable medical devices. The company offers dura membrane patches, regenerated oxidized cellulose, and craniomaxillofacial repair systems. It also offers ReDura, NeoDura, Recranio, and StypCel for neurosurgery, and 3D bioprinting applications serving patients internationally. Medprin Regenerative Medical Technologies Co., Ltd. was founded in 2008 and is based in Guangzhou, China.

Contact Information

Address No. 3 Yayingshi Road Huangpu District
Guangzhou, 510700
China
Phone -
Fax -

Top Executives

Name Age Since Title
Ling Liu 35 - Chairman of the Supervisory Board
Xian Zhuang 29 - Supervisor
Yuyu Yuan 43 - Chairman of the Board & GM
Li Jiang 47 - Director
Yahong Luo 55 - CFO, Deputy GM & Director
Xiaofeng Chen 67 - Independent Director
Xin Lu 60 - Independent Director
Guangmei Yan 66 - Independent Director
Meifu Yuan 51 - Director
Xiaoyan Long 39 2022 Board Secretary & Director
Haiying Zheng 54 - Director
Meiling Mo 28 - Supervisor
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

301033 Comments

Write your thoughts about Medprin Regenerative Medical Technologies Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email